Aberrant expression of β-dystroglycan may be due to processing by matrix metalloproteinases-2 and -9 in oral squamous cell carcinoma

Oral Oncology

Volumn 44, Issue 12, 2008, Pages 1139-1146

  Shang, Zheng Jun ^a   Ethunandan, Madanagopalan ^b   Górecki, Dariusz C ^c   Brennan, Peter A ^b  

^a WUHAN UNIVERSITY   (China)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Dystroglycan; Matrix metalloproteinase; Metastasis; Oral squamous cell carcinoma

Indexed keywords

1,10 PHENANTHROLINE; ALPHA DYSTROGLYCAN; BETA DYSTROGLYCAN; GELATINASE A; GELATINASE B;

ADULT; AMINO ACID ANALYSIS; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; WESTERN BLOTTING;

EID: 56249104133     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.02.016     Document Type: Article

References (23)

1. Hood J.D., and Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2 2 (2002) 91-100
2. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J 22 10 (2003) 2318-2323
3. Winder S.J. The complexities of dystroglycan. Trends Biochem Sci 26 2 (2001) 118-124
4. Williamson R.A., Henry M.D., Daniels K.J., Hrstka R.F., Lee J.C., Sunada Y., et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 6 6 (1997) 831-841
5. Durbeej M., Talts J.F., Henry M.D., Yurchenco P.D., Campbell K.P., and Ekblom P. Dystroglycan binding to laminin alpha1LG4 module influences epithelial morphogenesis of salivary gland and lung in vitro. Differentiation 69 2-3 (2001) 121-134
6. Brennana P.A., Jing J., Ethunandan M., and Górecki D.C. Dystroglycan complex in cancer. EJSO 30 6 (2004) 589-592
7. Henry M.D., Cohen M.B., and Campbell K.P. Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 32 8 (2001) 791-795
8. Losasso C., Di Tommaso F., Sgambato A., Ardito R., Cittadini A., Giardina B., et al. Anomalous dystroglycan in carcinoma cell lines. FEBS Lett 484 3 (2000) 194-198
9. Sgambato A., Migaldi M., Montanari M., Camerini A., Brancaccio A., Rossi G., et al. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 162 3 (2003) 849-860
10. Jing J., Lien C.F., Sharma S.J., Rice J., Brennan P.A., and Gorecki D.C. Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. Eur J Cancer 40 14 (2004) 2143-2151
11. Dang D., Yang Y., Li X., Atakilit A., Regezi J., Eisele D., et al. Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochem Biophys Res Commun 316 3 (2004) 937-942
12. Yamada H., Saito F., Fukuta-Ohi H., Zhong D., Hase A., Arai K., et al. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 10 15 (2001) 1563-1569
13. Sugita S., Saito F., Tang J., Satz J., Campbell K., and Südhof T.C. A stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol 154 2 (2001) 435-445
14. Sgambato A., and Brancaccio A. The dystroglycan complex: from biology to cancer. J Cell Physiol 205 2 (2005) 163-169
15. Sgambato A., De Paola B., Migaldi M., Di Salvatore M., Rettino A., Rossi G., et al. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 213 2 (2007) 528-539
16. Stetler-Stevenson W.G., Liotta L.A., and Kleiner Jr. D.E. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7 15 (1993) 1434-1441
17. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4 2 (1993) 197-250
18. Verstappen J., and Von den Hoff J.W. Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease. J Dent Res 85 12 (2006) 1074-1084
19. Tsai C.H., Hsieh Y.S., Yang S.F., Chou M.Y., and Chang Y.C. Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 6 (2003) 710-716
20. Durbeej M., Henry M.D., and Campbell K.P. Dystroglycan in development and disease. Curr Opin Cell Biol 10 5 (1998) 594-601
21. Gao Z.B., Duan Y.Q., Zhang L., Chen D.W., and Ding P.T. Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. Int J Mol Med 16 4 (2005) 599-603
22. de Vicente J.C., Fresno M.F., Villalain L., Vega J.A., and Hernández Vallejo G. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 41 3 (2005) 283-293
23. Delilbasi C.B., Okura M., Iida S., and Kogo M. Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol 40 2 (2004) 154-157